Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol-Myers Squibb reports positive Onglyza trial data

Bristol-Myers Squibb reports positive Onglyza trial data

29th June 2010

Bristol-Myers Squibb has posted new clinical trial data which demonstrates the effectiveness of Onglyza, its collaboratively-developed type 2 diabetes mellitus drug.

Results from the 52-week phase IIIb trial showed that adding Onglyza to a metformin therapy yielded non-inferior results in reducing glycosylated haemoglobin levels, when compared to titrated glipizide.

The drug, which was developed in conjunction with AstraZeneca, is already approved in the EU and US as an adjunct to a number of different anti-diabetic medications, including glyburide or thiazolidinedione.

Dr Burkhard Goke, professor of internal medicine at University Hospital Munich, said: “Many adult patients with type 2 diabetes need more than one therapy to help improve glycemic control and the data presented today adds to the body of evidence for Onglyza.”

Last week, Bristol-Myers Squibb and AstraZeneca reported data from a clinical trial of their diabetes drug dapagliflozin, showing the treatment’s efficacy in lowering glycosylated haemoglobin levels when compared to placebo.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.